Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow margin | (150.6%) | (117.5%) | (25.4%) | (143.2%) | (147.4%) | (442.0%) | (469.8%) | 3.5% | 12.9% | (8.5%) | (97.2%) | (39.8%) | 10.5% | 23.5% | 38.5% | 35.9% | 48.2% | 31.8% | 44.0% | 33.2% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is (11.0%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for Vertex Pharmaceuticals Incorporated have been 31.1% over the past three years, and 36.3% over the past five years.
As of today, Vertex Pharmaceuticals Incorporated's Free Cash Flow margin is (11.0%), which is higher than industry median of (753.4%). It indicates that Vertex Pharmaceuticals Incorporated's Free Cash Flow margin is Good.